Dimensional Fund Advisors
VRDN icon

Dimensional Fund Advisors’s Viridian Therapeutics VRDN Stock Holding History

Dimensional Fund Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$36.1M Buy
1,754,123
+142,602
+9% +$3.04M 0.01% 1747
2026
Q2 		$29.6M Buy
1,611,521
+1,081,758
+204% +$17.4M 0.01% 1856
2026
Q1 		$10.4M Sell
529,763
-25,831
-5% -$767K ﹤0.01% 2247
2025
Q4 		$17.3M Sell
555,594
-83,183
-13% -$2.28M ﹤0.01% 2046
2025
Q3 		$13.8M Buy
638,777
+153,079
+32% +$2.76M ﹤0.01% 2175
2025
Q2 		$6.79M Buy
+485,698
New +$6.59M ﹤0.01% 2427
2025
Q1 		– Sell
-55,924
Closed -$1.07M – 3358
2024
Q4 		$1.07M Sell
55,924
-271,156
-83% -$5.9M ﹤0.01% 2898
2024
Q3 		$7.44M Buy
327,080
+219,500
+204% +$3.59M ﹤0.01% 2402
2024
Q2 		$1.4M Buy
107,580
+97,510
+968% +$1.35M ﹤0.01% 2849
2024
Q1 		$176K Hold
10,070
– – ﹤0.01% 3201
2023
Q4 		$219K Hold
10,070
– – ﹤0.01% 3181
2023
Q3 		$154K Hold
10,070
– – ﹤0.01% 3254
2023
Q2 		$240K Sell
10,070
-856
-8% -$22K ﹤0.01% 3209
2023
Q1 		$278K Buy
+10,926
New +$350K ﹤0.01% 3140
2022
Q3 		$234K Hold
11,398
– – ﹤0.01% 3208
2022
Q2 		$132K Buy
+11,398
New +$153K ﹤0.01% 3291
2019
Q4 		– Sell
-13,637
Closed -$150K – 3403
2019
Q3 		$150K Sell
13,637
-294
-2% -$6.5K ﹤0.01% 3306
2019
Q2 		$428K Hold
13,931
– – ﹤0.01% 3213
2019
Q1 		$583K Sell
13,931
-527
-4% -$23.8K ﹤0.01% 3138
2018
Q4 		$657K Buy
14,458
+294
+2% +$17K ﹤0.01% 3102
2018
Q3 		$1.19M Sell
14,164
-153
-1% -$14.4K ﹤0.01% 3034
2018
Q2 		$1.38M Buy
14,317
+3,354
+31% +$355K ﹤0.01% 2962
2018
Q1 		$1.15M Buy
10,963
+6,611
+152% +$718K ﹤0.01% 2976
2017
Q4 		$681K Buy
4,352
+2,670
+159% +$340K ﹤0.01% 3053
2017
Q3 		$231K Buy
+1,682
New +$283K ﹤0.01% 3205

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Dimensional Fund Advisors's VRDN Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Viridian Therapeutics (VRDN) stake by 8.8% in Q3 2026, buying an estimated $3.04M and bringing the position to 1,754,123 shares worth $36.1M. The position accounts for 0.01% of the portfolio, ranked #1747.

Dimensional Fund Advisors first reported a position in VRDN in Q3 2017 and has held it in 25 quarters since. 94 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Dimensional Fund Advisors held 1,754,123 shares of Viridian Therapeutics worth $36.1M as of Q3 2026.
  • Dimensional Fund Advisors bought 142,602 Viridian Therapeutics shares in Q3 2026, an estimated $3.04M.
  • Viridian Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #1747 holding.
  • Dimensional Fund Advisors first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 25 quarters since.
  • 94 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.